partnership
Summit sells failed antibiotic to OpenAI-backed startup in $105M deal
Summit Therapeutics agreed to sell its failed antibiotic ridinilazole to OpenAI-backed startup Biossil in a $105 million deal.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Tue · 14 Jul
partnership
Summit Therapeutics agreed to sell its failed antibiotic ridinilazole to OpenAI-backed startup Biossil in a $105 million deal.
Markets open original ↗
product
Sunrun expanded its California distributed power plant's dispatch capacity to 425 megawatts to provide statewide grid relief.
Markets open original ↗
earnings
JA Solar Technology projects a H1 net loss of 2.4-2.9 billion yuan.
Markets open original ↗
funding
MDA Space announced the closing of its upsized bought deal offering of common shares.
Markets open original ↗
regulation
Agilent received FDA approval for its PD-L1 IHC 28-8 pharmDx diagnostic test covering esophageal and gastric cancers.
Markets open original ↗